2
MEETING VENUE HOTEL MICHELANGELO MILAN Piazza Luigi di Savoia, 6 - 20124 Milan, Italy Tel: +39 0267551 MEETING SECRETARIAT AND CME PROVIDER MI&T Srl Viale Carducci, 50 - 40125 Bologna - Italy Tel. +39 051 220427 Fax +39 051 0822077 [email protected] www.mitcongressi.it REGISTRATION FEE ELITA/ESOT Member € 100,00 - NonMember € 250,00 to register please access www.mitcongressi.it and click on ELITA/ESOT Monothematic Conference LIVER TRANSPLANTATION IN HCV OR HBV POSITIVE RECIPIENTS: WHERE WE ARE AND WHERE WE ARE GOING UNRESTRICTED GRANT BY ELITA/ESOT Monothematic Conference LIVER TRANSPLANTATION IN HCV OR HBV POSITIVE RECIPIENTS: WHERE WE ARE AND WHERE WE ARE GOING MILANO April 1, 2016 HOTEL MICHELANGELO Christophe Duvoux CHAIR Roberto Troisi VICE-CHAIR Wojtek Polak SECRETARY Gabriela Berlakovich TREASURER Renè Adam CUSTODIAN Luca Saverio Belli William Bennet Giacomo Germani Silvio Nadalin Martin Oliverius Krzysztof Zieniewicz Luca Saverio Belli Christophe Duvoux SILVER SPONSOR

LIVER REGISTRATION FEE TRANSPLANTATION IN HCV OR HBV

  • Upload
    others

  • View
    5

  • Download
    0

Embed Size (px)

Citation preview

Page 1: LIVER REGISTRATION FEE TRANSPLANTATION IN HCV OR HBV

MEETING VENUEHOTEL MICHELANGELO MILAN

Piazza Luigi di Savoia, 6 - 20124 Milan, ItalyTel: +39 0267551

MEETING SECRETARIAT AND CME PROVIDER

MI&T Srl Viale Carducci, 50 - 40125 Bologna - Italy Tel. +39 051 220427 Fax +39 051 [email protected] www.mitcongressi.it

REGISTRATION FEEELITA/ESOT Member € 100,00 - NonMember € 250,00

to register please access www.mitcongressi.it and click on ELITA/ESOT Monothematic Conference

LIVEr TrANSPLANTATION IN HCV Or HBV POSITIVE rECIPIENTS: wHErE wE ArE ANd wHErE wE ArE GOING

UNRESTRICTED GRANT BY

ELITA/ESOT Monothematic Conference

LIVER TRANSPLANTATIONIN HCV OR HBV POSITIVE RECIPIENTS: wHERE wE ARE AND wHERE wE ARE GOING

MILANOApril 1, 2016HOTEL MICHELANGELO

Christophe DuvouxCHAIr

roberto TroisiVICE-CHAIr

wojtek PolakSECrETArY

Gabriela BerlakovichTrEASUrEr

renè AdamCUSTOdIAN

Luca Saverio Belliwilliam Bennet

Giacomo GermaniSilvio Nadalin

Martin Oliverius Krzysztof Zieniewicz

Luca Saverio BelliChristophe Duvoux

SILVEr SPONSOr

Page 2: LIVER REGISTRATION FEE TRANSPLANTATION IN HCV OR HBV

8:00> 8:10 welcome and Introduction: L.S. Belli and C. Duvoux

8:10>10:30 SESSION 1 Antiviral therapy for HCV in the setting of Liver transplantation. what’s new since the ELITA Milan Conference 2015 Chairs: P. Burra and M. Berenguer

8:10>8:40 Summing up of 2015 ELITA guidelines L.S. Belli and C. Duvoux

8:40>8:55 The new weapons and their combinations in early 2016: what will change the landscape in compensated and de-compensated cirrhotics? T. Berg

8:55>9:10 Up-date on safety, post marketing toxicity and recent alerts of DAAs C. Hezode

9:10>9:25 DAAs and virological resistance in the setting of Liver transplantation: pre LT and pre ReLT resistance M. Puoti

9:25>9:35 Q&A

9:35>9:50 DAA in de-compensated cirrhotics: focus on possible de-listing L.S. Belli

9:50>10:05 Use of HCV positive Liver grafts in the DAA Era: can we reconsider it? M. Berenguer

10:05>10:20 Value-based Hepatology aspects: the clinician point of view. Focus on pre and post LT DAAs treatments and expected cost reductions M. Strazzabosco

10:20>10:30 Q&A

10:30>10:50 Coffee break 10:50>11:45 SESSION 2 ELITA guidelines for DAA use in the Liver transplant setting: time for an update

Round table M. Berenguer, I. Colle, T. Berg, S. Fagiuoli, G. Pageaux, M. Londoño, C. Hezode

11:45>12:35 SESSION 3 HBV infection and Liver transplantation: epidemiology and pre LT management Introduction: C. Duvoux Chairs: P. Muiesan and L. De Carlis

11:45>12:00 HBV/HDV and LT. Data from ELTR P. Burra

12:00>12:15 Impact of NUC therapy on Liver function in decompensated cirrhosis and virological criteria to be eligible for LT F. Durand

12:15>12:35 Prophylactic strategies in Europe in 2016. French and Italian surveys: the landscape C. Duvoux and R. Volpes

12:35>13:30 Lunch Break

13:30>15:30 SESSION 4 Management of HBV: transplant and post transplant issues Chairs: W. Polak and M. Buti

13:30>13:50 Is there a Virological rationale to combine NUC and HBIg in 2015? C. Feray

13:50>14:10 Combined HBIG/NUC prophylaxis: time for selective HBIG withdrawal long term? R. Esteban

14:10>14:30 Is 3rd generation “NUCs alone prophylaxis” after LT a safe option? J. Fung

Just a focus on:

14:30>14:45 Anti HBc+ve Liver grafts: which prophylaxis in which recipients? A. Coilly

14:45>15:00 HBsAg+ve grafts: which prophylaxis in which recipients? P. Andreone

15:00>15:15 HDV and Liver Transplantation: do HDV+ve recipients require a specific prophylaxis? M. Rizzetto

15:15>15:30 Vaccination for HBV and Liver transplantation: what’s new? F. Nevens

15:30>15:45 Coffee break

15:45>16:45 SESSION 5 Controversial aspects of HBV in the Liver transplant setting

Round table M. Rizzetto, M. Berenguer, M. Buti, R. Romagnoli, J. Fung, F. Nevens, F. Durand

16:45>17:00 An attempt to define the best decision making algorithm for HBV prophylaxis after Liver transplantation M. Buti

17:00 Closing remarks L.S. Belli and C. Duvoux

Pietro Andreone BOLOGNA, IT

Luca Saverio Belli MILAN, IT

Marina Berenguer VALENCIA, ESThomas Berg

LIPSIA, dEPatrizia Burra

PAdUA, ITMaria Buti

BArCELONA, ESAudrey Coilly

PArIS, FrIsabelle Colle

GENT, BELuciano De Carlis

MILAN, ITFrancois Durand

BEAUjON, FrChristophe Duvoux

PArIS, Frrafael Esteban

BArCELONA, ESStefano Fagiuoli

BErGAMO, ITCyrille Feray

PArIS, Frjames Fung

HONG KONG, CINAChristophe Hezode

PArIS, FrMaria Londoño

BArCELONA, ESVincenzo Mazzaferro

MILAN, ITPaolo Muiesan

BIrMINGHAM, UKFrederik Nevens

LEUVEN, BEGeorges-Philippe Pageaux

MONTPELLIEr, Frwojtek Polak

rOTTErdAM, NLMassimo Puoti

MILAN, ITMario Rizzetto

TUrIN, ITrenato Romagnoli

TUrIN, ITMario Strazzabosco

MILAN, IT - YALE, USAriccardo Volpes

PALErMO, IT